Li Yun, Chen Yaxi, Ruan Xiong Z
Centre for Lipid Research & Chongqing Key Laboratory of Metabolism on Lipid and Glucose The Second Affiliated Hospital Chongqing Medical University Chongqing China.
John Moorhead Laboratory Centre for Nephrology University College London London UK.
Pediatr Discov. 2023 Jun 12;1(1):e9. doi: 10.1002/pdi3.9. eCollection 2023 Jun.
A cluster of differentiation 36 (CD36), also known as fatty acid translocase, plays an important role in developing and progressing metabolic diseases. Soluble CD36 (sCD36), a circulating form of CD36, is identified in human plasma. Current studies have demonstrated that sCD36 is an early biomarker of type 2 diabetes (T2DM) and atherosclerosis risk and may act as a key molecule in organ cross-talks directly or indirectly. This review summarizes the cell sources, molecular structure, potential production mechanism, functions, and regulators of sCD36. We highlight the association of sCD36 with hyperlipidemia, metabolic inflammation, T2DM, cardiovascular disease, non-alcoholic fatty liver disease, diabetic kidney disease, and obesity. These studies suggest that sCD36 could be a useful biomarker for metabolic diseases in children and a potential therapeutic target in preventing metabolic diseases.
分化簇36（CD36），也称为脂肪酸转运蛋白，在代谢性疾病的发生和发展中起重要作用。可溶性CD36（sCD36）是CD36的一种循环形式，已在人体血浆中被鉴定出来。目前的研究表明，sCD36是2型糖尿病（T2DM）和动脉粥样硬化风险的早期生物标志物，可能直接或间接地作为器官相互作用中的关键分子。这篇综述总结了sCD36的细胞来源、分子结构、潜在产生机制、功能和调节因子。我们强调了sCD36与高脂血症、代谢性炎症、T2DM、心血管疾病、非酒精性脂肪性肝病、糖尿病肾病和肥胖症之间的关联。这些研究表明，sCD36可能是儿童代谢性疾病的有用生物标志物，也是预防代谢性疾病的潜在治疗靶点。
